Comparison of the Efficacy of Colistin Plus Tigecycline vs. Colistin Plus Meropenem in the Treatment of Carbapenem-Resistant Acinetobacter baumannii (CRAB): A randomized controlled trial
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 370
- 试验地点
- 1
- 主要终点
- Mortality
研究概览
简要总结
· Acinetobacter baumannii has evolved as a significant hospital pathogen by its ability to resist desiccation. Carbapenem resistance rates exceed 90%.Mortality rates for the most common CRAB infections, i.e., hospital-acquired pneumonia (HAP) and bloodstream infections (BSI), may approach 60%. Current antimicrobials for CRAB are polymyxins, tigecycline, and sometimes aminoglycosides. Various combinations of these drugs have been used for the treatment of CRAB infections. Combination therapies may be better at microbiologic eradication but not superior to monotherapy .This study will help in guiding the efficacy of combination therapy to inspire further novel therapeutic options against resistant microorganisms
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- Participant Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 70.00 Year(s)（—）
- 性别
- All
入选标准
- •All patients with VAP/HAP/BSI who are admitted with culture positive Acinetobacter baumanii in medical ICU.
- •Those who give consent for the study.
排除标准
- •Non-Acinetobacter baumanii VAP/HAP/BSI admitted in ICU
- •Superimposed infection during the treatment of CRAB infection
- •Extremes of age-Age less than 18 and more than 70 years of age.
结局指标
主要结局
Mortality
时间窗: Mortality will be seen within 28 days
次要结局
- Comorbid conditions, Physiological scores (APACHE II), microbiological clearance (14 & 28 days),Clinical response to drugs (14 & 28 days)
研究者
FARHEEN ahmed
AIIMS patna